PUBLISHER: The Business Research Company | PRODUCT CODE: 1957608
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957608
Personalized medicine biomarkers are distinct biological indicators used to customize medical treatments for individual patients according to their unique genetic, molecular, or physiological traits. These biomarkers can assist in predicting a patient's response to a specific drug, allowing doctors to select the most effective and safest treatment options.
The primary types of biomarkers in personalized medicine include genomic, proteomic, metabolic, and others. Genomic biomarkers are specific genes or genetic mutations that assist in understanding how diseases develop and progress in individuals. They are utilized for a range of disease indications, such as oncology, neurology, diabetes, autoimmune disorders, cardiology, and more, for various purposes including early detection or screening, diagnosis, treatment selection, and monitoring. They serve a variety of end users, including hospitals and clinics, pharmaceutical and biotechnology companies, diagnostic laboratories, and others.
Tariffs have affected the personalized medicine biomarkers market by increasing the cost of imported reagents, sequencing consumables, assay kits, and analytical components used in biomarker development and testing. These impacts have been most pronounced in genomic and proteomic biomarker segments, particularly in north america and europe where laboratory supply chains are globally diversified. Asia-pacific manufacturers have faced pricing pressure due to dependency on imported diagnostic inputs. However, tariffs have encouraged regional production of biomarker kits and localized manufacturing, supporting supply resilience and long-term cost optimization.
The personalized medicine biomarkers market research report is one of a series of new reports from The Business Research Company that provides personalized medicine biomarkers market statistics, including personalized medicine biomarkers industry global market size, regional shares, competitors with a personalized medicine biomarkers market share, detailed personalized medicine biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the personalized medicine biomarkers industry. This personalized medicine biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The personalized medicine biomarkers market size has grown rapidly in recent years. It will grow from $26.73 billion in 2025 to $31.34 billion in 2026 at a compound annual growth rate (CAGR) of 17.3%. The growth in the historic period can be attributed to advances in genomic research, rising cancer incidence, growth of targeted therapies, increased use of molecular diagnostics, regulatory support for precision medicine.
The personalized medicine biomarkers market size is expected to see rapid growth in the next few years. It will grow to $58.8 billion in 2030 at a compound annual growth rate (CAGR) of 17.0%. The growth in the forecast period can be attributed to expansion of personalized therapeutics, rising demand for early disease detection, growth in pharmacogenomics, increasing investment in biomarker discovery, wider adoption across non-oncology indications. Major trends in the forecast period include rising adoption of precision treatment approaches, increasing use of biomarkers in oncology care, growing integration of companion diagnostics, expansion of predictive and prognostic biomarkers, higher focus on treatment response monitoring.
The increasing prevalence of chronic diseases is expected to drive the growth of the personalized medicine biomarkers market in the coming years. Chronic diseases are long-lasting medical conditions that develop gradually and persist for a year or longer, requiring continuous medical care or limiting everyday activities. The rise in chronic diseases is attributed to unhealthy lifestyle habits, poor diets, insufficient physical activity, and elevated stress levels. Personalized medicine biomarkers assist in customizing treatments for chronic diseases by identifying effective therapies, forecasting disease progression, and reducing adverse effects based on individual genetic and molecular profiles. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based health authority, reported that by 2050, the number of new cancer cases is projected to exceed 35 million, marking a 77% increase from the estimated 20 million cases in 2022. Hence, the rising prevalence of chronic diseases is fueling the growth of the personalized medicine biomarkers market.
Major companies operating in the personalized medicine biomarkers market are concentrating on securing regulatory approvals, such as companion diagnostic approval, to improve precision oncology by quickly matching patients with targeted therapies. Companion diagnostic approval is the regulatory authorization granted by a health authority (such as the FDA) for a diagnostic test specifically designed to identify patients most likely to benefit from a particular therapeutic product or who may face an increased risk of adverse reactions. For example, in August 2024, Illumina, Inc., a US-based biotechnology company, received Food and Drug Administration (FDA) approval for its cancer biomarker test along with two companion diagnostics. The test employs next-generation sequencing (NGS) technology to detect genetic mutations in cancer cells, allowing clinicians to select the most appropriate treatments based on individual biomarkers. This approval represents a significant advancement in precision oncology, aiming to enhance the speed and accuracy of treatment selection for cancer patients, ultimately improving personalized care.
In February 2025, Renovaro Inc., a US-based biotechnology firm, merged with BioSymetrics Inc. to advance AI-driven biomarker discovery and precision medicine. The merger is intended to improve drug development and enable more personalized treatment strategies, tackling complex diseases through innovative, data-driven methods. BioSymetrics Inc. is a Canada-based phenomics-focused drug discovery company that combines clinical and experimental data using machine learning to promote precision medicine.
Major companies operating in the personalized medicine biomarkers market are AbbVie Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Merck KGaA, GE Healthcare, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., DH Life Sciences LLC, Myriad Genetics Inc., Guardant Health Inc., Cardiff Oncology Inc., 23andMe Inc., Coriell Life Sciences Inc.
North America was the largest region in the personalized medicine biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized medicine biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the personalized medicine biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The personalized medicine biomarkers market consists of sales of biomarker-based diagnostic kits, reagents, testing platforms, epigenetic biomarkers, companion diagnostics, predictive biomarkers, prognostic biomarkers, and multi-omics biomarkers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Personalized Medicine Biomarkers Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses personalized medicine biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for personalized medicine biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The personalized medicine biomarkers market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.